This ASX medical device company has a Trump tariff exemption

Did this ASX stock just receive a golden ticket?

| More on:
Ecstatic woman on her phone giving a fist pump after reading some good news.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ResMed Inc (ASX: RMD) could be counting its lucky stars this week as it might be one of the few companies handed a tariff exemption from the Trump administration. 

The company develops, manufactures, distributes, and markets medical devices and cloud-based software solutions.

It operates through two segments, Sleep and Respiratory Care, and Software as a Service (SaaS).

According to Australian Financial Review, it has received an exemption from Donald Trump's trade tariffs. 

This means exports from its manufacturing hubs in Australia and Singapore can likely avoid the US president's global trade war.

Chief executive Mick Farrell told AFR the company manufactures sleep devices and masks in Australia and Singapore, which are protected under the Nairobi Protocol. This international agreement guarantees duty-free treatment for products that help people with disabilities.

We have a tariff exemption under this decades-old protection. The tax revenue wouldn't be material to the US government and there's no reason for them to want to turn over something and get constituents or citizens upset about not caring about people with disabilities.

ResMed rising

ResMed shares are up more than 5% over the last month. 

Created with Highcharts 11.4.3ResMed PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

This was possibly due to a strong Q3 update.

For the three months ended 31 March, ResMed reported an 8% increase in revenue to US$1.3 billion.

This was driven by increased demand for its sleep devices and masks portfolio, as well as solid growth across its Residential Care Software business.

Despite the positive tariff exemption news, Farrell reinforced there is still some uncertainty. Referring to the White House's control over government agencies that make decisions on tariffs, he said that "nothing is rock-solid when an administration, particularly this one, can make changes very quickly".

According to the AFR, ResMed is doubling its manufacturing capacity in the United States with a new plant in Calabasas, California, a move Farrell said was not a reaction to Trump administration policies.

What are brokers saying?

It seems brokers are bullish on this blue-chip stock, with multiple brokers placing attractive price targets on the stock thanks to the tariff exemption and strong financials. 

At the time of writing, shares are trading at $36.75 each. 

Macquarie has a price target $48.00, indicating a 30% upside. 

Analysts at Goldman Sachs have retained their conviction buy rating on ResMed shares with an improved price target of $49.30. This was also influenced by the tariff exemption.

Jed Richards from Shaw and Partners says Resmed is a buy

Richards said:

On April 24, ResMed posted an 8 per cent increase in revenue in the third quarter of fiscal year 2025. The gross margin improved 140 basis points to 59.3 per cent. Income from operations increased 14 per cent.

ResMed's innovative products and steady revenue growth make it a solid investment. 

Bell Potter has a $43.31 price target.

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Woman with an amazed expression has her hands and arms out with a laptop in front of her.
Share Gainers

Why GenusPlus, NIB, Superloop, and Titomic shares are racing higher today

These shares are starting the week on a positive note. But why?

Read more »

Man with rocket wings which have flames coming out of them.
Share Gainers

Up 99% in a year, guess which ASX 300 stock is rocketing higher again today

Investor are piling into the $1.6 billion ASX 300 company again today. But why?

Read more »

Two brokers analysing stocks.
Energy Shares

Santos shares push higher on takeover update

What is the latest on this potential deal? Let's find out.

Read more »

A female soldier flies a drone using hand-held controls.
Share Market News

DroneShield shares charge higher on more big news

This high-flying stock has announced another important contract win.

Read more »

A business woman looks unhappy while she flies a red flag at her laptop.
Share Market News

These are the 10 most shorted ASX shares

Let's see which shares short sellers are targeting this week.

Read more »

a man in a business suit sits at his laptop computer at his desk and smiles broadly in an office setting, giving an air of optimism and confidence.
Opinions

This ASX 200 share has made the most money for my portfolio. I'm expecting a lot more

There’s one key reason why I’m expecting strong growth from this stock.

Read more »

A male investor sits at his desk looking at his laptop screen holding his hand to his chin pondering whether to buy Macquarie shares
Share Market News

These ASX 200 stocks doubled in FY25. Can they do it again in FY26?

Let's find out.

Read more »

Woman on her phone with diagrams of tech sector related elements linking with each other.
Share Market News

Which magnificent 7 stock would I buy today with $5,000?

One stands above the rest.

Read more »